Skip to content

Comparison of the efficacy of SVF injection in the treatment of alopecia

Comparison of the efficacy, safety, tolerability and satisfaction of SVF injection in the treatment of androgenetic alopecia

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200127046282N8
Enrollment
24
Registered
2022-03-28
Start date
2022-04-19
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hair loss. Androgenic alopecia, unspecified

Interventions

Intervention 1: Intervention group: One side of the patient's head is treated with SVF injection. Intervention 2: Control group: One side of the patient's head is treated with normal saline injection.

Sponsors

Skin and Stem Cell Research Center, Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: men and women with inherited hormonal hair loss Age 18 years and older and less than 50 years Hamilton scores 2 to 5 in men and Ludwig scores 1 to 3 in women Complete patient consent to participate in the project

Exclusion criteria

Exclusion criteria: Platelet disorders Thrombocytopenia Patients receiving anticoagulants Patients with malignancy Receiving chemotherapy during the last 5 years Patients with sepsis Being a smoker Pregnancy Active wound or infection at the treatment site Do not receive any topical or systemic medication in the last 3 months Women with hyperprolactinemia Women with hormonal disorders or polycystic ovaries

Design outcomes

Primary

MeasureTime frame
The amount of hair loss. Timepoint: Before treatment and two month after the last session. Method of measurement: Trichoscan.

Secondary

MeasureTime frame
Side effects. Timepoint: One week after session. Method of measurement: Questionnaire and visit.;Satisfaction. Timepoint: Two months after the last session. Method of measurement: Questionnaire and visit.;Tolerability. Timepoint: Each session after transplantation. Method of measurement: Questionnaire and visit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Skin and stem Cell Research Center, Tehran University of Medical Sciences

sonazarebio@gmail.com+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026